These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 12761258

  • 1. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial.
    Praga M, Gutiérrez E, González E, Morales E, Hernández E.
    J Am Soc Nephrol; 2003 Jun; 14(6):1578-83. PubMed ID: 12761258
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 3. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group.
    Donadio JV, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC.
    J Am Soc Nephrol; 1999 Aug; 10(8):1772-7. PubMed ID: 10446945
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
    Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H.
    Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
    [Abstract] [Full Text] [Related]

  • 5. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
    Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P, Remuzzi G.
    J Am Soc Nephrol; 1998 Dec; 9(12):2308-17. PubMed ID: 9848785
    [Abstract] [Full Text] [Related]

  • 6. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
    Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM.
    Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
    [Abstract] [Full Text] [Related]

  • 7. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.
    Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F.
    J Am Soc Nephrol; 2004 Jan; 15(1):157-63. PubMed ID: 14694168
    [Abstract] [Full Text] [Related]

  • 8. Segmental glomerulosclerosis in IgA nephropathy after renal transplantation: relationship with proteinuria and therapeutic response to enalapril.
    Jeong HJ, Kim YS, Kwon KW, Kim MS, Kim S, Choi KH, Lee HY, Han DS, Park K.
    Clin Transplant; 2003 Apr; 17(2):108-13. PubMed ID: 12709075
    [Abstract] [Full Text] [Related]

  • 9. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
    Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T.
    J Am Soc Nephrol; 2007 Jun; 18(6):1880-8. PubMed ID: 17513327
    [Abstract] [Full Text] [Related]

  • 10. Elevation of von Willebrand factor levels in patients with IgA nephropathy: effect of ACE inhibition.
    Hernández E, Toledo T, Alamo C, Mon C, Rodicio JL, Praga M.
    Am J Kidney Dis; 1997 Sep; 30(3):397-403. PubMed ID: 9292569
    [Abstract] [Full Text] [Related]

  • 11. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis.
    Woo KT, Lau YK, Wong KS, Chiang GS.
    Kidney Int; 2000 Dec; 58(6):2485-91. PubMed ID: 11115082
    [Abstract] [Full Text] [Related]

  • 12. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
    Pozzi C, Del Vecchio L, Locatelli F.
    G Ital Nefrol; 2002 Dec; 19(5):523-8. PubMed ID: 12439840
    [Abstract] [Full Text] [Related]

  • 13. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
    Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K, Ito E, Waga S.
    Pediatr Int; 2004 Oct; 46(5):576-9. PubMed ID: 15491387
    [Abstract] [Full Text] [Related]

  • 14. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C, Rizza V, Paparella M, Casellato D, Napodano P, Olivieri G, D'Amico G.
    J Nephrol; 2009 Oct; 22(3):387-96. PubMed ID: 19557716
    [Abstract] [Full Text] [Related]

  • 15. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
    Cruzado JM, Poveda R, Ibernón M, Díaz M, Fulladosa X, Carrera M, Torras J, Bestard O, Navarro I, Ballarín J, Romero R, Grinyó JM.
    Nephrol Dial Transplant; 2011 Nov; 26(11):3596-602. PubMed ID: 21393611
    [Abstract] [Full Text] [Related]

  • 16. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
    Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi G, Pecchini P, Rustichelli R, Finocchiaro P, Del Vecchio L, Locatelli F.
    J Nephrol; 2013 Nov; 26(1):86-93. PubMed ID: 22460183
    [Abstract] [Full Text] [Related]

  • 17. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy.
    Remuzzi A, Perico N, Sangalli F, Vendramin G, Moriggi M, Ruggenenti P, Remuzzi G.
    Am J Physiol; 1999 Mar; 276(3):F457-66. PubMed ID: 10070170
    [Abstract] [Full Text] [Related]

  • 18. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 19. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
    Renke M, Tylicki L, Rutkowski P, Rutkowski B.
    Scand J Urol Nephrol; 2004 Jul; 38(5):427-33. PubMed ID: 15764256
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease.
    Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, Wallner M, Auinger M, Arias I, Schneider B, Mayer G.
    Kidney Blood Press Res; 1998 Jul; 21(1):66-9. PubMed ID: 9661139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.